Compare Amazon.com Inc (AMZN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Amazon (AMZN) trades at $244.19, down 0.47% on the day but maintains strong bullish technical momentum with support at $241. The company demonstrates robust fundamentals with 2025 revenue of $716.92B and net income of $77.67B, representing 10.83% profit margin. Recent Q1 2026 earnings beat expectations with EPS of $2.78 versus $1.63 expected, while analyst consensus remains overwhelmingly positive with 88.3% buy ratings.

Amazon's outlook remains favorable with continued revenue growth and expanding profitability, though significant capital expenditures for AI infrastructure and competitive pressures in e-commerce present risks. The stock trades at a P/E of 29.35, offering growth potential relative to the consensus price target of $320.75, representing 31% upside from current levels.

INO trades at $1.18, down 0.84% with bearish technical signals. The company shows minimal revenue of $65K against massive losses, with a net margin of -130,000% and negative cash flow. Recent news highlights an active FDA review for INO-3107 with an October 2026 decision date, while multiple law firms investigate potential fiduciary breaches by directors.

The investment case hinges on the binary FDA approval of INO-3107. While analyst consensus is 53% buy-rated, fundamental metrics are deeply negative. Key risks include clinical trial outcomes, cash burn, and legal scrutiny. Upside depends entirely on successful drug commercialization.